Clinical Trials Directory

Trials / Completed

CompletedNCT02481609

NAC Trial for Anosmia

Pilot Study of Topical Intranasal N-acetyl Cysteine Administration for the Treatment of Anosmia

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
29 (actual)
Sponsor
University of Miami · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia (a loss of the sense of smell). This drug is already approved by the Food and Drug Administration (FDA) for oral or pulmonary (lung) inhaled use for other medical conditions. However, there is research evidence that the medication may promote nerve recovery (help nerves work better after they are damaged). Since anosmia involves nerve problems, we believe the nasal spray may help treat anosmia. The medication has been in use for many years for other conditions, without safety problems.

Conditions

Interventions

TypeNameDescription
DRUGN-acetyl cysteine (NAC)

Timeline

Start date
2014-07-01
Primary completion
2017-12-01
Completion
2017-12-01
First posted
2015-06-25
Last updated
2018-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02481609. Inclusion in this directory is not an endorsement.

NAC Trial for Anosmia (NCT02481609) · Clinical Trials Directory